Clinical Trial Update: A Safety and Efficacy Trial of a Combination of Bendamustine, Rituximab and Lenalidomide in Patients With Chronic Lymphocytic Leukemia [Phase 1, Phase 2]

View source ↗

Summary

A Phase 1/2 trial evaluating the three-drug combination of bendamustine, rituximab, and lenalidomide in chronic lymphocytic leukemia has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Lymphocytic Leukemia

Drugs mentioned

• Bendamustine (Bendamustine)
• Lenalidomide (lenalidomide)
• Rituximab (rituximab)

Snippet

Sponsor: German CLL Study Group | Conditions: Chronic Lymphocytic Leukemia | Phase 1, Phase 2 | Status: COMPLETED